Trials / Unknown
UnknownNCT06126263
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
Comparative Effectiveness of Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections: A Target Trial Emulation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- National Institutes of Health Clinical Center (CC) · NIH
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to emulate a hypothetical target pragmatic multi-center, non-blinded trial of adult inpatients in the PINC AITM dataset with B-lactam treated culture confirmed monomicrobial invasive Group A streptococcus (GAS) between the years 2015-2021
Conditions
- Streptococcal Sepsis
- Invasive Group A Beta-Haemolytic Streptococcal Disease
- Necrotizing Soft Tissue Infection
- Infection, Bloodstream
- Infection, Bacterial
- Streptococcal Toxic Shock Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linezolid | Adjunctive antitoxin therapy |
| DRUG | Clindamycin | Adjunctive antitoxin therapy |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2024-04-30
- Completion
- 2024-06-30
- First posted
- 2023-11-13
- Last updated
- 2023-11-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06126263. Inclusion in this directory is not an endorsement.